Don’t Trade in the Dark—Get Your Pre-Market Report Every Day.Join Now
Healthcare | Mid Cap
Health Score : 7.40Emcure Pharmaceuticals Ltd presents a strong, though mixed, financial picture. The company's standout strengths are its exceptional profitability and explosive growth. It demonstrates a remarkable ability to generate high profits from its operations and is expanding its revenue and earnings at an impressive rate. Furthermore, its financial structure is very stable, with a very low reliance on debt, which significantly reduces long-term financial risk. However, this positive picture is contrasted by significant weaknesses. The company's short-term liquidity is tight, suggesting potential challenges in meeting immediate financial obligations with readily available cash. More notably, its operational efficiency is a major concern, as it struggles to use its assets effectively to generate sales. This combination of high growth and low efficiency could indicate operational bottlenecks or growing pains. The future outlook is promising due to strong market demand and profitability, but its success hinges on addressing these underlying efficiency and liquidity issues.
Health Score : 7.40Emcure Pharmaceuticals Ltd presents a strong, though mixed, financial picture. The company's standout strengths are its exceptional profitability and explosive growth. It demonstrates a remarkable ability to generate high profits from its operations and is expanding its revenue and earnings at an impressive rate. Furthermore, its financial structure is very stable, with a very low reliance on debt, which significantly reduces long-term financial risk. However, this positive picture is contrasted by significant weaknesses. The company's short-term liquidity is tight, suggesting potential challenges in meeting immediate financial obligations with readily available cash. More notably, its operational efficiency is a major concern, as it struggles to use its assets effectively to generate sales. This combination of high growth and low efficiency could indicate operational bottlenecks or growing pains. The future outlook is promising due to strong market demand and profitability, but its success hinges on addressing these underlying efficiency and liquidity issues.
Overall Valuation Score
Markets Depth NSE
Buy Orders
Bid
Quantity
Orders
No buy depth
Total
0
0
Sell Orders
Ask
Quantity
Orders
No sell depth
Total
0
0
Markets Today NSE
High
0.00
Low
0.00
Open
0.00
Close
0.00
Prev Close
0.00
Avg Price
0.00
Volume
0
Last Traded Quantity
0
Last Traded Time
N/A
Price Movement Indicator
Today's Low: 0.00
Today's High: 0.00
P/E RATIO (TTM)
47.75
Industry Median
30.91
Mid Cap Median
44.19
P/E RATIO
37.86
P/B RATIO
7.07
Industry Median
3.69
Mid Cap Median
6.64
P/S RATIO
3.81
Industry Median
3.74
Mid Cap Median
6.84
Others
PEG RATIO
2.15
EV/EBITDA RATIO
19.25
The Calculations Shown Above Are Based on the Last Traded Price (LTP) of ₹1845.9 as on Sep 1, 2026.
Growth Score : 10.00The company is experiencing a period of exceptional and robust expansion. It shows outstanding growth across all major financial metrics, including sales, operating profits, and earnings for shareholders. This powerful upward trend indicates strong market acceptance of its products or services and highly effective business strategies. The outlook based on this momentum is very positive, suggesting continued market share gains and value creation.
Revenue Growth RateExcellentOperating Profit Growth RateExcellentEarnings Per Share (EPS) GrowthExcellentAsset Growth RateExcellentNet Income Growth RateExcellent| Growth Ratios | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Revenue Growth Rate | 16.33 | 2.24 | 11.23 | 18.59 | 16.57 |
| Operating Profit Growth Rate | 9.38 | -11.13 | 4.06 | 19.43 | 26.96 |
| Earnings Per Share (EPS) Growth | 58.19 | -19.66 | -6.53 | 30.76 | 35.6 |
| Asset Growth Rate | -11.04 | 10.18 | 16.2 | 5.36 | 18.35 |
| Net Income Growth Rate | 67.78 | -20.06 | -6.05 | 33.9 | 33.1 |
Revenue Growth Rate
Operating Profit Growth Rate
Earnings Per Share (EPS) Growth
Asset Growth Rate
Net Income Growth Rate
Peer Comparison empowers investors to evaluate a company against its industry peers using key financial metrics like P/E ratio, EPS, and profit margins. It helps identify whether a company is overvalued, undervalued, or performing in line with competitors. Investors can use this data to spot opportunities, assess risks, and make informed decisions. This contextual view adds depth beyond standalone company analysis.
| NO | Company Name | Health Score | P/E Ratio | Valuation | OPM | EPS | Latest Profit & Loss |
|---|---|---|---|---|---|---|---|
| 1 | J B Chemicals & Pharmaceuticals Ltd | 8.14 | 54.51 | Overvalued | 1107.00 | 41.98 | 709.00 |
| 2 | Gland Pharma Ltd | 7.91 | 46.11 | Overvalued | 1630.00 | 78.78 | 1027.00 |
| 3 | Neuland Laboratories Ltd | 7.84 | 81.16 | Highly Overvalued | 574.00 | 283.01 | 364.00 |
| 4 | Granules India Ltd | 7.73 | 34.87 | Highly Overvalued | 1185.00 | 16.17 | 595.00 |
| 5 | Ajanta Pharma Ltd | 7.72 | 41.47 | Neutral | 1395.00 | 75.78 | 1056.00 |
| 6 | Alembic Pharmaceuticals Ltd | 7.60 | 24.58 | Undervalued | 1118.00 | 32.58 | 671.00 |
| 7 | Emcure Pharmaceuticals Ltd | 7.40 | 37.86 | Neutral | 1865.00 | 38.64 | 941.00 |
| 8 | Syngene International Ltd | 7.16 | 51.15 | Neutral | 918.00 | 7.55 | 317.00 |
| 9 | ERIS Lifesciences Ltd | 7.15 | 29.07 | Neutral | 1120.00 | 17.61 | 648.00 |
| 10 | Ipca Laboratories Ltd | 6.33 | 44.19 | Overvalued | 1979.00 | 44.64 | 1184.00 |
| 11 | Piramal Pharma Ltd | 5.83 | -87.02 | Neutral | 922.00 | 5.26 | -326.00 |
| 12 | Jubilant Pharmova Ltd | 5.71 | 36.27 | Neutral | 1260.00 | 1.25 | 398.00 |
| 13 | Natco Pharma Ltd | 5.69 | 10.72 | Neutral | 1436.00 | 71.55 | 1418.00 |
| 14 | Wockhardt Ltd | 5.07 | 141.16 | Neutral | 652.00 | 19.51 | 199.00 |
| 15 | Pfizer Ltd | 3.45 | 46.48 | Neutral | -82.00 | 157.92 | 300.00 |
0 Credits RemainingUnlock Deep Technical Insights in Seconds Only with Dhanarthi AI
Overall Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Strong Bearish
Market Sentiment
Analysis Driven By 26 Technical Indicators From The 1 Hour Timeframe
Trend Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Strong Bearish
Momentum Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Volatility Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bearish
Volume Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Analyzing moving average trends and crossovers. Green/Red badges indicate if the current condition passes or fails.
Comparing stock price performance (normalized) against benchmark indices over time.
Recent daily trading volume represented as a bar chart, alongside historical averages.
Current closing price relative to the 52-week highest and lowest prices.
No Stock Reports Available at This Moment.
Emcure Pharmaceuticals Ltd. is a prominent Indian pharmaceutical company focused on developing, manufacturing, and marketing a diverse portfolio of pharmaceutical products. It specializes in branded and generic formulations, biologics, and APIs, catering to various therapeutic areas across domestic and international markets, underpinned by a robust R&D infrastructure.
P/E Ratio (TTM): Price to Earnings ratio shows how much an investor pays for every rupee of the company's earnings. Emcure Pharmaceuticals Ltd's P/E ratio (TTM) is 47.75, compared to the industry median of 30.91 and large cap median of 44.19.
P/B Ratio: Price to Book ratio compares a company's market price to its book value per share. Emcure Pharmaceuticals Ltd's P/B ratio is 7.07, compared to the industry median of 3.69 and large cap median of 6.64.
P/S Ratio: Price to Sales ratio compares a company's market value to its total revenue. Emcure Pharmaceuticals Ltd's P/S ratio is 3.81, compared to the industry median of 3.74 and large cap median of 6.84.
PEG Ratio: PEG ratio adjusts the P/E ratio for expected earnings growth. Emcure Pharmaceuticals Ltd's PEG ratio is 2.15.
EV/EBITDA Ratio: This ratio compares a company's enterprise value to its earnings before interest, tax, depreciation, and amortization. Emcure Pharmaceuticals Ltd's EV/EBITDA ratio is 19.25.
Return on Equity (ROE): ROE measures how much profit a company generates from shareholders' invested capital. Emcure Pharmaceuticals Ltd's ROE is 19.01%.
Return on Assets (ROA): ROA measures how efficiently a company converts its assets into net profit. Emcure Pharmaceuticals Ltd's ROA is 19.40%.
Return on Capital Employed (ROCE): ROCE measures how efficiently a company generates profit from all the capital it employs. Emcure Pharmaceuticals Ltd's ROCE is 24%.
Operating Margin: Operating margin shows what percentage of revenue remains after covering operating expenses. Emcure Pharmaceuticals Ltd's operating margin is 20.26%.
Net Margin: Net margin shows what percentage of revenue converts into final net profit. Emcure Pharmaceuticals Ltd's net margin is 10.22%.
Current Ratio: The current ratio measures a company's ability to pay short-term liabilities using short-term assets. Emcure Pharmaceuticals Ltd's current ratio is 1.48.
Debt to Equity Ratio: This ratio shows the proportion of debt a company uses relative to shareholders' equity. Emcure Pharmaceuticals Ltd's debt-to-equity ratio is 0.12.
Interest Coverage Ratio: This ratio shows how easily a company can pay interest on its outstanding debt from its operating earnings. Emcure Pharmaceuticals Ltd's interest coverage ratio is 9.94.
Dividend Per Share (DPS): DPS shows the total dividend paid per share in the latest financial year. Emcure Pharmaceuticals Ltd's DPS is ₹0.
Earnings Per Share (EPS): EPS shows how much profit is allocated to each outstanding share. Emcure Pharmaceuticals Ltd's EPS is 35.60.
(Source line: "Ratios as of 25 Sept 2026, based on last traded price of ₹1845.90. Data sourced from BSE/NSE Exchange Filings & Public Terminal Data.")
Founded: 1981
Headquarters: Pune, Maharashtra
Core Offerings: Branded Generics, Generic Formulations, Biologics, Active Pharmaceutical Ingredients (APIs), Contract Manufacturing
Stock Listing: NSE (EMCURE), BSE (544210)
Promoter: Mehta Family / Satish Mehta
Founded in 1981 by Satish Mehta, Emcure Pharmaceuticals began its commercial operations in 1983. The company expanded its product portfolio and manufacturing capabilities over the 1990s and 2000s, including establishing USFDA-approved facilities. Through strategic alliances and acquisitions, it strengthened its market presence and diversified into complex generics and biologics in the 2010s. Emcure filed its Draft Red Herring Prospectus (DRHP) for an Initial Public Offering (IPO) in 2021, and refiled it in 2023, signaling its intent for public listing.
| Segment Name | Revenue % | EBITDA |
|---|---|---|
| India Formulations | 59% | Operating Profit |
| International Formulations | 30% | Operating Profit |
| APIs, Biologics & CDMO | 11% | Operating Profit |
India Formulations: Strong market presence in diverse therapeutic areas such as gynecology, blood-related products, pain & analgesics, anti-infectives, and cardiology, supported by an extensive distribution network.
International Business: Operates in over 70 countries, with a significant focus on regulated markets like the US, Europe, and Canada, as well as emerging markets, primarily offering generic formulations.
APIs & Biologics: Engaged in the development and manufacturing of Active Pharmaceutical Ingredients (APIs) and has a growing emphasis on biosimilar products targeting complex and critical diseases.
Satish Mehta: Managing Director & CEO. Founder of Emcure Pharmaceuticals, he possesses over 40 years of experience in the pharmaceutical industry and has been the driving force behind the company's growth. Gattu V. Prasad: Chairman (Non-Executive). An experienced pharmaceutical executive, previously associated with Dr. Reddy's Laboratories, providing strategic oversight.
Zuventus Healthcare Ltd. (India)
Emcure Pharmaceuticals Inc. (USA)
Genera Inc. (USA)
Filed Draft Red Herring Prospectus (DRHP) for an Initial Public Offering (IPO) in 2021, refiled an updated DRHP in 2023.
The Emcure Pharmaceuticals Ltd share price today is ₹1845.90 on NSE (EMCURE), as of 26 Sept 2026.
As of 25 Sept 2026, Emcure Pharmaceuticals Ltd share price is ₹1845.90, with previous close ₹1845.90. Today's range is ₹1845.90 to ₹1845.90. The 52-week range is ₹1356 to ₹2100.70.
As of today, Emcure Pharmaceuticals Ltd's market cap is ₹35,072.1 crore (Large Cap).
Emcure Pharmaceuticals Ltd's current P/E ratio is 47.75, compared to the Financial Services sector average of 31.
Emcure Pharmaceuticals Ltd's current P/B ratio is 7.07.
Emcure Pharmaceuticals Ltd's current dividend yield is N/A. Last dividend of ₹N/A - Company not publicly listed. per share was declared on N/A.
Emcure Pharmaceuticals Ltd's EPS (TTM) is ₹35.60.
Emcure Pharmaceuticals Ltd. is a prominent Indian pharmaceutical company focused on developing, manufacturing, and marketing a diverse portfolio of pharmaceutical products. It specializes in branded and generic formulations, biologics, and APIs, catering to various therapeutic areas across domestic and international markets, underpinned by a robust R&D infrastructure.
Emcure Pharmaceuticals Ltd is promoted by Mehta Family / Satish Mehta, holding 77.87% as of 25 Sept 2026.
Emcure Pharmaceuticals Ltd is listed on NSE (EMCURE) and BSE (544210). Its next quarterly results are expected on N/A - Company not publicly listed..
